Literature DB >> 24901209

Immunosafety and chronic toxicity evaluation of monomethoxypoly(ethylene glycol)-b-poly(lactic acid) polymer micelles for paclitaxel delivery.

Chang Li1, Yan Shen1, Chunmeng Sun1, Cheraga Nihad1, Jiasheng Tu1.   

Abstract

To investigate the physicochemical properties, immunosafety and chronic toxicity of monomethoxypoly(ethylene glycol)-b-poly(lactic acid) (mPEG-PLA), a copolymer used as a carrier for paclitaxel (PTX) delivery. The H-Nuclear Magnetic Resonance (H-NMR), dynamic light scattering and fluorescence probe technique were conducted to determine the physicochemical properties of mPEG-PLA copolymer. PTX-loaded polymeric micelles were characterized regarding their particle size, entrapment efficiency (EE), drug loading (DL), in vitro drug release and hemolysis rate. The complement activation in human serum and mast cells degranulation were performed by ELISA and RBL-2H3 cell line in vitro, respectively. The chronic toxicity study was carried out on beagle dogs. The optimized PTX-loaded mPEG-PLA (40/60) micelles showed a particle size of 37 nm and EE of 98.0% with a DL of 17.0% w/w. Transmission electron microscopy (TEM) analyses showed that mPEG-PLA (40/60) micelles have spherical shape with dense core. In vitro release study showed a sustained release for 24 h, and the hemolysis study revealed that mPEG-PLA (40/60) was a safe nanocarrier for intravenous administration. mPEG-PLA (40/60) showed a lower complement activation ability compared to mPEG-PLA (50/50) and Cremophor® EL (Cr EL). Furthermore, the chronic toxicity of PTX-loaded mPEG-PLA (40/60) micelles was significantly lower than those of mPEG-PLA (50/50) and Cr EL.

Entities:  

Keywords:  Complement activation; mPEG-PLA; mast cell degranulation; paclitaxel; pseudoallergy

Mesh:

Substances:

Year:  2014        PMID: 24901209     DOI: 10.3109/10717544.2014.920429

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  5 in total

1.  Preparation of mPEG-b-PLA/TM-2 Micelle Lyophilized Products by Mixed Lyoprotectors and Antitumor Effect In Vivo.

Authors:  Ying Zhang; Yi Liu; Na Wang; Hongbing Liu; Jingxin Gou; Haibing He; Yu Zhang; Tian Yin; Yanjiao Wang; Xing Tang
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

2.  Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles.

Authors:  Jian Hou; E Sun; Zhen-Hai Zhang; Jing Wang; Lei Yang; Li Cui; Zhong-Cheng Ke; Xiao-Bin Tan; Xiao-Bin Jia; Huixia Lv
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations.

Authors:  Xiao Hu; Feifei Yang; Yonghong Liao; Lin Li; Lan Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy.

Authors:  Weiping Ji; Bo Wang; Qiuping Fan; Chao Xu; Youwu He; Youfen Chen
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

Review 5.  Hazard Assessment of Polymeric Nanobiomaterials for Drug Delivery: What Can We Learn From Literature So Far.

Authors:  Sandra Jesus; Mélanie Schmutz; Claudia Som; Gerrit Borchard; Peter Wick; Olga Borges
Journal:  Front Bioeng Biotechnol       Date:  2019-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.